4 / 11
Page 54
Notes:
conferenceseries
.com
10
th
International Conference on
February 22-23, 2018 | Paris, France
Vascular Dementia
Volume 8
Journal of Alzheimers Disease & Parkinsonism
ISSN: 2161-0460
Vascular Dementia 2018
February 22-23, 2018
The 2018 Stockport vascular neurocognitive disorder investigation, treatment and annual review
guidelines (including the spectrum from mild vascular cognitive impairment to vascular dementia)
supporting primary and secondary care physicians
Sally Gilmour
1
, Peter Ngoma
2
and
Rachel Price
1
1
The Meadows Hospital-Stockport Pennine Care NHS Trust, UK
2
Stepping Hill Hospital-Stockport NHS Foundation Trust, UK
V
ascular neurocognitive disorder patients may already be receiving adequate treatment for other cardiovascular disease,
but we should reassess ensuring optimum secondary cardiovascular risk prevention with new location target end organ
damage. A minority are not receiving secondary cardiovascular prevention as vascular neurocognitive disorder is their first
diagnosis of cardiovascular system disease. Many of these newly diagnosed patients may not subsequently receive secondary
cardiovascular risk prevention perhaps especially with subcortical gradual reduction in activities of daily living and change
to personality. There is no research evidence to treat cerebrovascular disease which is proportional to that expected for the
patient age on MRI or CT brain. The MRI Fazekas score should reflect the clinical indication of brain target organ vascular
disease more so than expected age related change. Gradient echo assesses micro hemorrhage which may mean anti-platelets or
anticoagulants are contra-indicated, prevalent in cerebral amyloid angiopathy and mixed vascular and Alzheimer’s pathology.
Patient treatment advice leaflets assist informed shared decisions; although there is no consensus from research evidence
that treating blood pressure, cholesterol and using anti-platelets or anticoagulation will reduce cognitive decline in vascular
neurocognitive disorder, there is evidence for secondary cardiovascular prevention once there is diagnosis of target organ
damage to the brain with vascular pathological brain target damage. Risk consideration assesses patients and carers, signpost to
healthy lifestyle advocated by Lancet 2017 Dementia Commission. Vascular neurocognitive disorder support healthy lifestyle
published leaflets examples include ‘4ME’.
Biography
Sally Gilmour has worked in primary care for 18 years and in 2011 worked in Old Age Psychiatry with Dr. Katherine Hayden developing an interest in vascular
dementia. She has produced a dementia podcast and a dementia review template; integrated into the Stockport primary care computer system and has lectured to
the National Driving Assessors course regarding dementia. She works solely in Stockport Old Age Psychiatry since 2015.
s.gilmour@nhs.netSally Gilmour et al., J Alzheimers Dis Parkinsonism 2018, Volume 8
DOI: 10.4172/2161-0460-C1-037